Reports
Sale
Retinal Vein Occlusion Market Size, Share, Trends, Report: By Type: Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion; By Condition: Non-Ischemic, Ischemic; By Diagnosis: Optical Coherence Tomography (OCT), Fundoscopic Examination, Others; By Treatment Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Retinal Vein Occlusion Market Outlook
The retinal vein occlusion market size was valued at USD 12.4 billion in 2023, driven by the rising incidence of geriatric population. The market is expected to grow at a CAGR of 13.03% during the forecast period of 2024-2032, with the values likely to rise from USD 14 billion in 2024 to USD 37.2 billion by 2032.
Retinal Vein Occlusion: Introduction
Retinal vein occlusion is a condition characterized by the blockage of small veins carrying blood away from the retina. It may induce sudden blurring or vision loss in one part or the entire eye. Retinal vein occlusion is caused by hardening of veins (atherosclerosis) and blood clot formation. The venous blockage can be broadly divided into two categories, namely, central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Treatment includes anti-vascular endothelial growth factor injections or focal laser procedures among others. The treatment may vary from patient to patient.
Retinal Vein Occlusion Market Analysis
With the increasing prevalence of sedentary lifestyle and obesity, the incidence of atherosclerosis, also known as hardening of the arteries, has increased. Atherosclerosis is one of the major causes of retinal vein occlusion along with other risk factors like diabetes, high blood pressure, macular edema, and glaucoma. The growing occurrence of these factors has fueled the retinal vein occlusion market demand.
Retinal vein occlusion management has been a key area of attention amongst the researchers. With the rising number of drug approvals for disease management, the market value is anticipated to grow in the forecast period. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on two phase III studies showcasing early and persistent vision improvements in patients with the condition.
The retinal vein occlusion market growth is driven by the advent of new diagnostic and management tools for facilitating better understanding of the pathophysiology of the disease. Multimodal imaging techniques such as optical coherence tomography (OCT), optical coherence tomography angiography, choroidal imaging and fundus fluorescein angiography are commonly used diagnostic methods.
Retinal Vein Occlusion Market Segmentation
Market Breakup by Type
- Branch Retinal Artery Occlusion
- Central Retinal Vein Occlusion
Market Breakup by Condition
- Non-Ischemic
- Ischemic
Market Breakup by Diagnosis
- Optical Coherence Tomography (OCT)
- Fundoscopic Examination
- Fluorescein Angiography
- Others
Market Breakup by Treatment Type
- Antivascular Endothelial Growth Factor
- Corticosteroid Drugs
- Laser Retinal Photocoagulation
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Retinal Vein Occlusion Market Overview
The retinal vein occlusion market share has been dominated by the United States in the historical period. The presence of key healthcare companies can be considered as a major factor fueling the market size. With a robust healthcare infrastructure, scientists can easily integrate numerous technical advancements into their research and develop effective treatment alternatives for the patients.
In Europe, the population is at a higher risk of retinal vein occlusion largely due to high geriatric population. Identifying the risk, the government has been proactive in providing the right awareness to the people. Moreover, the region has been witnessing mergers and acquisitions amongst MedTech companies to expand their product portfolio and cater to the market demand.
Retinal Vein Occlusion Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Allergan
- Bayer AG
- IRIDEX Corporation
- Lumenis
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals
- Merck & Co.
- Carl Zeiss
- AbbVie Inc.
- CalciMedica Inc.
- Outlook Therapeutics, Inc.
- Kodiak Sciences Inc.
- Aerie Pharmaceuticals Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Condition |
|
| Breakup by Diagnosis |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Retinal Vein Occlusion Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Retinal Vein Occlusion Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.1 Germany Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.2 France Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.3 Italy Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.4 Spain Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.4 Japan Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
6 Retinal Vein Occlusion Market Overview – 7MM
6.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
6.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
7 Retinal Vein Occlusion Market Landscape – 7MM
7.1 Retinal Vein Occlusion Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Retinal Vein Occlusion Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Type
7.2.3 Analysis by Route of Administration
8 Retinal Vein Occlusion Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Retinal Vein Occlusion Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Retinal Vein Occlusion Market Segmentation – 7MM
11.1 Retinal Vein Occlusion Market by Type
11.1.1 Market Overview
11.1.2 Branch Retinal Artery Occlusion
11.1.3 Central Retinal Vein Occlusion
11.2 Retinal Vein Occlusion Market by Condition
11.2.1 Market Overview
11.2.2 Non-Ischemic
11.2.3 Ischemic
11.3 Retinal Vein Occlusion Market by Diagnosis
11.3.1 Market Overview
11.3.2 Optical Coherence Tomography (OCT)
11.3.3 Fundoscopic Examination
11.3.4 Fluorescein Angiography
11.3.5 Others
11.4 Retinal Vein Occlusion Market by Treatment Type
11.4.1 Market Overview
11.4.2 Antivascular Endothelial Growth Factor
11.4.3 Corticosteroid Drugs
11.4.4 Laser Retinal Photocoagulation
11.4.5 Others
11.5 Retinal Vein Occlusion Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Ambulatory Surgical Centers
11.5.5 Homecare Settings
11.5.6 Others
11.6 Retinal Vein Occlusion Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Retinal Vein Occlusion Market
12.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
12.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
12.3 Retinal Vein Occlusion Market by Disease Type
12.4 Retinal Vein Occlusion Market by Treatment Type
13 EU-4 and United Kingdom Retinal Vein Occlusion Market
13.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
13.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
13.3 Germany Retinal Vein Occlusion Market Overview
13.3.1 Retinal Vein Occlusion Market by Disease Type
13.3.2 Retinal Vein Occlusion Market by Treatment Type
13.4 France Retinal Vein Occlusion Market Overview
13.4.1 Retinal Vein Occlusion Market by Disease Type
13.4.2 Retinal Vein Occlusion Market by Treatment Type
13.5 Italy Retinal Vein Occlusion Market Overview
13.5.1 Retinal Vein Occlusion Market by Disease Type
13.5.2 Retinal Vein Occlusion Market by Treatment Type
13.6 Spain Retinal Vein Occlusion Market Overview
13.6.1 Retinal Vein Occlusion Market by Disease Type
13.6.2 Retinal Vein Occlusion Market by Treatment Type
13.7 United Kingdom Retinal Vein Occlusion Market Overview
13.7.1 Retinal Vein Occlusion Market by Disease Type
13.7.2 Retinal Vein Occlusion Market by Treatment Type
14 Japan Retinal Vein Occlusion Market
14.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
14.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
14.3 Retinal Vein Occlusion Market by Disease Type
14.4 Retinal Vein Occlusion Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Allergan
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Bayer AG
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 IRIDEX Corporation
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Lumenis
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Novartis AG
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 F. Hoffmann-La Roche Ltd
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Regeneron Pharmaceuticals
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Merck & Co.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Carl Zeiss
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 AbbVie Inc.
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 CalciMedica Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Outlook Therapeutics, Inc.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Kodiak Sciences Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Aerie Pharmaceuticals Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Retinal Vein Occlusion Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 12.4 billion in 2023, driven by the increasing incidence of geriatric population.
The market is anticipated to grow at a CAGR of 13.03% during the forecast period of 2024-2032, likely to reach a market value of USD 37.2 billion by 2032.
The market demand is driven by the rising prevalence of atherosclerosis, which has become common due to the unhealthy lifestyle, obesity, and dietary habits in the modern-day scenario.
The current market trend surrounds the increasing drug approvals for disease management. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on the positive results from two phase III studies.
Based on treatment types, the market is divided into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation and others.
Branch retinal artery occlusion and central retinal vein occlusion are types of retinal occlusions in the market.
Optical coherence tomography (OCT), fundoscopic examination, and fluorescein angiography, among others are the common diagnosis methods in the market.
Based on condition, the market is divided into non-ischemic and ischemic.
Major end users include hospitals, clinics, ambulatory surgical centers, and homecare settings.
The major regions of the market include the United States, Japan, and EU-4, which is further segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Allergan, Bayer AG, IRIDEX Corporation, Lumenis, Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Merck & Co., Carl Zeiss, AbbVie Inc., CalciMedica Inc., Outlook Therapeutics, Inc., Kodiak Sciences Inc., and Aerie Pharmaceuticals Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER